The lack of success in clinical trials involving α7-nAChR ligands in Alzheimer's disease or schizophrenia has reduced the enthusiasm for this target and consequently, many pharmaceutical companies have discontinued their research efforts in this field (Bertrand and Terry, 2018). This evidence concerns the gene CHRNA7 and early-onset autosomal dominant Alzheimer disease.